classification	minimum_neoantigens	disease	oncotree_term	oncotree_code	context	therapy_name	therapy_strategy	therapy_type	therapy_sensitivity	therapy_resistance	favorable_prognosis	predictive_implication	preferred_assertion	description	source_type	citation	url	doi	pmid	nct	last_updated
High		Non-Small Cell Lung Cancer	Non-Small Cell Lung Cancer	NSCLC		Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	1			Clinical evidence		"In a cohort of 34 non-small cell lung cancer patients treated with pembrolizumab, an increased candidate neoantigen burden was associated with a higher chance of DCB and an improved PFS (median 14.5 vs. 3.5 months)."	Journal	"Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124-8."	https://doi.org/10.1126/science.aaa1348	10.1126/science.aaa1348	25765070		3/12/17